RXi Pharmaceuticals Profile

USD 0.05  2.3%

RXi Pharmaceuticals exotic insider transaction detected

RXi Pharmaceuticals Corporation insider trading alert for general transaction of common stock $0.0001 par value by Geert Cauwenbergh, President CEO, on October 2, 2017. This event was filed by Rxi Pharmaceuticals Corp with SEC on 2017-10-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

RXi Pharmaceuticals Summary

RXi Pharmaceuticals Corporation (RXII) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 15 people. RXi Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Nano-Cap' category with current market capitalization of 9.19 M. RXi Pharmaceuticals Corporation conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 4.26 M outstanding shares of which 1.76 M shares are at this time shorted by private and institutional investors with about 4.32 trading days to cover. RXI PHARMACEUTICA currently holds about 3.58 M in cash with (9.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Check RXi Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 2.12HorizonTargetOdds Above 2.12
3.29%30 days 2.12 96.67%
Based on normal probability distribution, the odds of RXi Pharmaceuticals to move above current price in 30 days from now is roughly 97.0% (This RXi Pharmaceuticals Corporation probability density function shows the probability of RXi Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Myda Advisors LlcCommon Shares41.6 K134 K
Morgan StanleyCommon Shares20.7 K67 K
Anson Funds Management LpWarrants2.2 M1.2 M
View RXi Pharmaceuticals Diagnostics

Selected RXi Pharmaceuticals Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

RXi Pharmaceuticals Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for RXi Pharmaceuticals Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 15 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameRXi Pharmaceuticals Corporation
President CEO, DirectorGeert CauwenberghView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
Business Address257 Simarano Drive
ExchangeNasdaq Capital Markets
IndustryPharmaceutical Products
Contact Number508 767 3861
Related EntityRXIIW
CurrencyUSD - US Dollar


RXi Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
8.0Strong Buy1Odds
RXi Pharmaceuticals Corporation current and past analyst recommendations published by number of research institutions as well as average analyst consensus
RXi Pharmaceuticals Analyst Advice  


RXi Pharmaceuticals Earnings Estimates
RXi Pharmaceuticals Corporation normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


RXi Pharmaceuticals Corporate Directors
Robert Bitterman Director, MBA
Keith Brownlie Director
Jonathan Freeman Independent Director, MBA
Additionally take a look at Your Equity Center. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.